PFIZER INC Long-Term Debt, Maturity, Year Three
PFIZER INC (PFE) had Long-Term Debt, Maturity, Year Three of $4.83 billion as of 2017-10-01, per its 10-Q filed 2017-11-09.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree · last filed 2017-11-09
- 2017-10-01: Long-Term Debt, Maturity, Year Three $4.83B.
- 2017-07-02: Long-Term Debt, Maturity, Year Three $4.77B.
- 2017-04-02: Long-Term Debt, Maturity, Year Three $4.68B.
- 2016-12-31: Long-Term Debt, Maturity, Year Three $3.35B.
| Period end | Long-Term Debt, Maturity, Year Three |
|---|---|
| 2017-10-01 | $4.83B 10-Q · filed 2017-11-09 |
| 2017-07-02 | $4.77B 10-Q · filed 2017-08-10 |
| 2017-04-02 | $4.68B 10-Q · filed 2017-05-11 |
| 2016-12-31 | $3.35B 10-K · filed 2017-02-23 |
| 2016-10-02 | $3.62B 10-Q · filed 2016-11-10 |
| 2016-07-03 | $3.63B 10-Q · filed 2016-08-11 |
| 2015-12-31 | $2.40B 10-K · filed 2016-02-29 |
| 2015-09-27 | $2.40B 10-Q · filed 2015-11-05 |
| 2014-12-31 | $3.96B 10-K · filed 2015-02-27 |
| 2014-09-28 | $4.16B 10-Q · filed 2014-11-06 |
| 2014-06-29 | $4.39B 10-Q · filed 2014-08-07 |
| 2013-12-31 | $4.41B 10-K · filed 2014-02-28 |
| 2013-09-29 | $3.03B 10-Q · filed 2013-11-08 |
| 2013-06-30 | $2.93B 10-Q · filed 2013-08-09 |
| 2013-03-31 | $3.06B 10-Q · filed 2013-05-10 |
| 2012-12-31 | $3.06B 10-K · filed 2013-02-28 |
| 2011-12-31 | $3.99B 10-K · filed 2012-02-28 |
| 2010-12-31 | $4.08B 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |